Kathleen Liu, MD, PhD, MAS
Professor of Medicine and Anesthesia in the Divisions of Nephrology and Critical Care Medicine; Medical Director of the Medical Intensive Care Unit and the Apheresis/Hemodialysis Unit at the University of California, San Francisco
This lectureship was established to honor Dr. Shaul G. Massry for his scientific achievements and his contributions to the kidney healthcare community and to the National Kidney Foundation.
Kathleen Liu is Professor of Medicine and Anesthesia in the Divisions of Nephrology and Critical Care Medicine and the Medical Director of the Medical Intensive Care Unit and the Apheresis/Hemodialysis Unit at the University of California, San Francisco. Her research has focused on acute kidney injury and the acute respiratory distress syndrome, with an emphasis on biomarkers and clinical trials.
Dr. Liu has been an active member of numerous protocol development committees for the NHLBI ARDS Network and PETAL Network. She has co-led Phase 1 and 2 trials of mesenchymal stromal cell therapy for ARDS. During the COVID-19 pandemic, she was a Co-Principal investigator for the I-SPY COVID-19 trial, an open-label, phase 2 platform multicenter trial focused on novel therapies in patients with severe COVID-19. Dr. Liu was a Steering Committee Member for the NIDDK funded Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study focused on long term outcomes of AKI. She is the current external steering committee chair for the NIDDK-funded Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) study. Dr. Liu chairs the American Society of Nephrology Kidney Health Guideline Oversight Committee and is a member of the ASN AKI!Now workgroup.
Dr. Liu's research has focused on acute kidney injury and the acute respiratory distress syndrome, with an emphasis on biomarkers and clinical trials.